Aurisco Pharmaceutical (605116.SH): The net income for the first half of the year was 0.189 billion yuan, an increase of 96.66% compared to the same period last year.

Gelonghui Finance · Aug 28 03:34

On August 28, Gelonhui announced its semi-annual report. In the first half of 2024, the company achieved revenue of 0.731 billion yuan, an increase of 32.21% compared to the same period last year; it achieved a net income of 0.189 billion yuan attributable to the shareholders of the listed company, a 96.66% increase over the same period last year. The company's revenue, net income attributable to shareholders of the listed company, and net income attributable to shareholders of the listed company excluding non-recurring gains and losses for the current period achieved significant growth compared to the same period last year, mainly due to: 1. The company continues to focus on its core business, with continuous steady growth in sales of advantageous active pharmaceutical ingredients; 2. Formulated products are gradually increasing in volume, and the market expansion is further reflected, which is a completely new area compared to the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

奥锐特(605116.SH)：上半年净利润1.89亿元 同比增长96.66%

Aurisco Pharmaceutical (605116.SH): The net income for the first half of the year was 0.189 billion yuan, an increase of 96.66% compared to the same period last year.

Risk Disclaimer

Statement

奥锐特(605116.SH)：上半年净利润1.89亿元同比增长96.66%